Clinical Trial Detail

NCT ID NCT03650894
Title Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
Recruitment Not yet recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Providence Health & Services
Indications

Her2-receptor negative breast cancer

Therapies

Bicalutamide + Ipilimumab + Nivolumab

Age Groups: adult senior

Additional content available in CKB BOOST